Product Information
GS IBUPROFEN 200 MG TABLET is a generic product labeled by L. Perrigo Company, priced at $0.0331 per EA under NDC 00113121285. Its NADAC has been published 216 times since Aug 17, 2022.
FDA first approved this application on Dec 8, 1987.
Strength
200 mg/1
Manufacturer
L. Perrigo CompanyNDC
00113121285
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
IBUPROFENApproval Type
Generic (ANDA)
FDA Application
ANDA072096FDA Approved
12/8/1987
On Market Since
10/19/2020
Pharmacological Classes
Price Statistics
The NADAC for GS IBUPROFEN 200 MG TABLET has been published 216 times since Aug 17, 2022, and over the history we have for it it has declined 4.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0331 per EA |
|---|---|
| All-time high | $0.0370 (Nov 12, 2025) |
| All-time low | $0.0300 (Apr 17, 2024) |
| 52-week high | $0.0370 |
| 52-week low | $0.0320 |
| Median price | $0.0336 |
| Average price | $0.0338 |
| Largest weekly change | -13.7% (Apr 17, 2024) |
| Weeks tracked | 216 |
| Tracking since | Aug 17, 2022 |
Generic Alternatives
The matcher finds 9 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 19% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
L. Perrigo Company manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Ibuprofen market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Nonsteroidal Anti-inflammatory Drug class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of GS IBUPROFEN 200 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for GS IBUPROFEN 200 MG TABLET, manufactured by L. Perrigo Company, is $0.0331 per EA (NDC 00113121285), effective Sep 30, 2026.
How has the price of GS IBUPROFEN 200 MG TABLET changed over time?
Over the history we have for it, the NADAC for GS IBUPROFEN 200 MG TABLET has declined 4.6%. It has been tracked across 216 weekly CMS publications since Aug 17, 2022.
What are the highest and lowest recorded NADAC prices for GS IBUPROFEN 200 MG TABLET?
Since Aug 17, 2022, the NADAC for GS IBUPROFEN 200 MG TABLET has ranged from a low of $0.0300 (Apr 17, 2024) to a high of $0.0370 (Nov 12, 2025), with a median of $0.0336 per EA.
Are there cheaper alternatives to GS IBUPROFEN 200 MG TABLET?
Yes. 9 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, IBUPROFEN 200 MG TABLET, is $0.0269 per EA — about 19% below GS IBUPROFEN 200 MG TABLET.
Who manufactures GS IBUPROFEN 200 MG TABLET?
GS IBUPROFEN 200 MG TABLET (NDC 00113121285) is labeled by L. Perrigo Company, and CMS classifies it as a generic product.